Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.45 |
| ▸ | GRM5 | P41594 | 8/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222886 | 0.92 | NAMPT (0.52) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL18326659 | 0.89 | NAMPT (0.49) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL17229879 | 0.88 | GRM1 (0.50) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL2297459 | 0.83 | NAMPT (0.58) | NAMPTPDK4GRM1GRM5TNK2 | |
| SCHEMBL794011 | 0.83 | NAMPT (0.45) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL4153073 | 0.82 | CYP11B2 (0.57) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL29579841 | 0.82 | CYP11B2 (0.57) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL28672677 | 0.81 | GRM1 (0.56) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL2908091 | 0.81 | NAMPT (0.60) | NAMPTPDK4CYP11B2GRM1GRM5 | |
| SCHEMBL29227506 | 0.81 | NAMPT (0.60) | NAMPTPDK4CYP11B2GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | NAMPT 773/4885PDK4 1672/4885CYP11B2 67/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | NAMPT 773/4885PDK4 1672/4885CYP11B2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.